血府逐瘀胶囊对高脂合并心梗大鼠心肾功能的影响及作用机制探讨
|
摘要
背景
近年来,心肾综合征备受临床关注,其定义为“心脏和肾脏中某一个脏器的急性或慢性功能不全导致另一个脏器出现急性或慢性功能障碍的临床综合征”。心肾综合征病理机制复杂,是临床常见的疑难重症。依照不同发病特点,将其分为五型,但各型临床流行病学资料及治疗手段依然有限。心肾综合征的病理机制主要有血流动力学改变、炎症反应、RAAS过度激活、交感神经系统激活、NO-ROS失衡、贫血与铁缺乏等方面,上述各种机制相互影响,互相促进,最终形成恶性循环。本课题将初步观察炎症反应在心肾综合征中的作用。研究表明,血清总胆固醇或低密度脂蛋白胆固醇升高是心脑血管疾病的独立危险因素之一。为此,对血脂异常的防治必须及早给予重视,但我国目前血脂控制达标率不足30%,高脂血症的防治工作任重而道远。众多研究发现,以血府逐瘀汤为代表的活血化瘀治则治疗心、肾疾病疗效显著,并能有效的降低血脂水平,显示出良好前景。
目的
通过本研究,以期明确大鼠心梗后心肾功能变化及炎症因子表达情况,本研究主要观察ICAM-1和IL一6。并探索活血化瘀治则对模型动物肾脏损害的干预情况及作用环节,为缺血性心脏病肾损害的基础研究及防治对策提供方法和思路。
方法
参照文献方法,采用结扎大鼠左冠状动脉前降支的方法制备大鼠心肌缺血模型,动物分为正常对照组、正常对照假手术组、高脂对照组、高脂假手术组、高脂模型组、血府逐瘀汤5倍组、血府逐瘀汤10倍组,每组动物8只,术后饲养14天后取材,检测心电图、血尿生化、血清中炎性因子、肾组织形态学变化以及肾脏代谢组学变化。
结果
1、活血化瘀药物治疗后模型动物缺血心电图阳性率降低；2、高脂大鼠心肌梗死后血肌酐明显升高(P<0.05),内生肌酐清除率明显下降(P<0.05)；3、高脂大鼠心肌梗死后血清ICAM-1、IL-6含量明显升高(P<0.01)；4、活血化瘀药物治疗后模型动物血肌酐有下降趋势、内生肌酐清除率提高,但未见统计学差异(P>0.05)。血清炎症因子ICAM-1、IL-6的含量较模型组略有降低,但未见统计学差异(P>0.05)。
结论
高脂大鼠心肌梗死后会出现肾脏损害,并可见循环中炎症因子表达升高,血府逐瘀对肾功能有一定改善作用。血府逐瘀胶囊治疗可以降低大鼠血清胆固醇及低密度脂蛋白含量。
Background
Cardiorenal syndrome receives much concern in recent years. The latest definition of CRS was "a pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of1organ may induce acute or chronic dysfunction of the other". The pathologic mechanism of CRS is very complicated. It's a difficult and complicated diseases in clinical work. According to the different pathogenesis characteristics, the CRS was divided into five types. The data of clinical epidemiologic investigation and therapy methods is still limited. The main pathologic mechanism of CRS were hemodynamic changes, inflammatory response, over-activation of RAAS, activation of sympathetic nervous, NO-ROS imbalance, anemia and iron deficiency and so on. They interacte and promote each other. A vicious circle will formate in final. The current project will make a deep research on the role of inflammatory response in cardiorenal syndrome. The results show that elevated serum total cholesterol or LDL cholesterol is an independent risk factor for coronary heart disease and ischemic stroke. So, we must give attention to early prevention and treatment of dyslipidemia. But China's current lipid control compliance rate is still less than30%. There is a long way to prevent and control hyperlipidemia. Many studies have found that promoting blood circulation therapy(Xuefuzhuyutang as the representative) can get significant effect in treatment of heart and kidney disease, and it can effectively reduce blood lipid levels.
Objective
In this study, the main object is to clear the change of heart anf kidney function, and the inflammatory factors expression in kidney injury. The main indicator are ICAM-1and NF-κB. To explore the intervention effect of promoting blood circulation therapy. Provide methods and clues for basic research and prevention countermeasures in CRS.
Methods
According to the methods in literaries, we lagated the LAD to make the mode of myocardial ischemia. Animals was divited into normal control group, normal control sham operation group, high-fat control group, Fat sham surgery group, Model group, Xuefuzhuyu five times group, Xuefuzhuyu ten times group,8rats in each group. Before drawing materials, all the rats received feeding for14days. And then, we check the ECG, blood and urine biochemistry, Inflammatory Factors in Blood serum, the nephrotic management histological changes and metabolomics changes of the kidney.
Results
1.The positive rate of ischemic ECG decreased after the therapy of promoting blood circulation and removing blood stasis;2.The serum creatinine increased and creatinine clearance rate (Ccr) declined after MI in hyperlipidemia rats(P<0.05);3.The serum level of ICAM-1,IL-6increased after the MI(P<0.01);4. After the therapy of promoting blood circulation and removing blood stasis, we can observe the downward trend of serum creatinine and the upward trend of Ccr, but no significant difference(P>0.05). At the same time, the serum level of ICAM-1,IL-6slightly lower than model group, but no significant difference(P>0.05).
Conclusion
Kidney injuey could be observed after myocardial ischemia in hyperlipidemia rats, and the expression of inflammatory factors was increased. Promoting blood circulation therapy could reduce the degree of renal impairment caused by myocardial ischemia and reduce the level of TC and LDL-C.
近年来,心肾综合征备受临床关注,其定义为“心脏和肾脏中某一个脏器的急性或慢性功能不全导致另一个脏器出现急性或慢性功能障碍的临床综合征”。心肾综合征病理机制复杂,是临床常见的疑难重症。依照不同发病特点,将其分为五型,但各型临床流行病学资料及治疗手段依然有限。心肾综合征的病理机制主要有血流动力学改变、炎症反应、RAAS过度激活、交感神经系统激活、NO-ROS失衡、贫血与铁缺乏等方面,上述各种机制相互影响,互相促进,最终形成恶性循环。本课题将初步观察炎症反应在心肾综合征中的作用。研究表明,血清总胆固醇或低密度脂蛋白胆固醇升高是心脑血管疾病的独立危险因素之一。为此,对血脂异常的防治必须及早给予重视,但我国目前血脂控制达标率不足30%,高脂血症的防治工作任重而道远。众多研究发现,以血府逐瘀汤为代表的活血化瘀治则治疗心、肾疾病疗效显著,并能有效的降低血脂水平,显示出良好前景。
目的
通过本研究,以期明确大鼠心梗后心肾功能变化及炎症因子表达情况,本研究主要观察ICAM-1和IL一6。并探索活血化瘀治则对模型动物肾脏损害的干预情况及作用环节,为缺血性心脏病肾损害的基础研究及防治对策提供方法和思路。
方法
参照文献方法,采用结扎大鼠左冠状动脉前降支的方法制备大鼠心肌缺血模型,动物分为正常对照组、正常对照假手术组、高脂对照组、高脂假手术组、高脂模型组、血府逐瘀汤5倍组、血府逐瘀汤10倍组,每组动物8只,术后饲养14天后取材,检测心电图、血尿生化、血清中炎性因子、肾组织形态学变化以及肾脏代谢组学变化。
结果
1、活血化瘀药物治疗后模型动物缺血心电图阳性率降低；2、高脂大鼠心肌梗死后血肌酐明显升高(P<0.05),内生肌酐清除率明显下降(P<0.05)；3、高脂大鼠心肌梗死后血清ICAM-1、IL-6含量明显升高(P<0.01)；4、活血化瘀药物治疗后模型动物血肌酐有下降趋势、内生肌酐清除率提高,但未见统计学差异(P>0.05)。血清炎症因子ICAM-1、IL-6的含量较模型组略有降低,但未见统计学差异(P>0.05)。
结论
高脂大鼠心肌梗死后会出现肾脏损害,并可见循环中炎症因子表达升高,血府逐瘀对肾功能有一定改善作用。血府逐瘀胶囊治疗可以降低大鼠血清胆固醇及低密度脂蛋白含量。
Background
Cardiorenal syndrome receives much concern in recent years. The latest definition of CRS was "a pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of1organ may induce acute or chronic dysfunction of the other". The pathologic mechanism of CRS is very complicated. It's a difficult and complicated diseases in clinical work. According to the different pathogenesis characteristics, the CRS was divided into five types. The data of clinical epidemiologic investigation and therapy methods is still limited. The main pathologic mechanism of CRS were hemodynamic changes, inflammatory response, over-activation of RAAS, activation of sympathetic nervous, NO-ROS imbalance, anemia and iron deficiency and so on. They interacte and promote each other. A vicious circle will formate in final. The current project will make a deep research on the role of inflammatory response in cardiorenal syndrome. The results show that elevated serum total cholesterol or LDL cholesterol is an independent risk factor for coronary heart disease and ischemic stroke. So, we must give attention to early prevention and treatment of dyslipidemia. But China's current lipid control compliance rate is still less than30%. There is a long way to prevent and control hyperlipidemia. Many studies have found that promoting blood circulation therapy(Xuefuzhuyutang as the representative) can get significant effect in treatment of heart and kidney disease, and it can effectively reduce blood lipid levels.
Objective
In this study, the main object is to clear the change of heart anf kidney function, and the inflammatory factors expression in kidney injury. The main indicator are ICAM-1and NF-κB. To explore the intervention effect of promoting blood circulation therapy. Provide methods and clues for basic research and prevention countermeasures in CRS.
Methods
According to the methods in literaries, we lagated the LAD to make the mode of myocardial ischemia. Animals was divited into normal control group, normal control sham operation group, high-fat control group, Fat sham surgery group, Model group, Xuefuzhuyu five times group, Xuefuzhuyu ten times group,8rats in each group. Before drawing materials, all the rats received feeding for14days. And then, we check the ECG, blood and urine biochemistry, Inflammatory Factors in Blood serum, the nephrotic management histological changes and metabolomics changes of the kidney.
Results
1.The positive rate of ischemic ECG decreased after the therapy of promoting blood circulation and removing blood stasis;2.The serum creatinine increased and creatinine clearance rate (Ccr) declined after MI in hyperlipidemia rats(P<0.05);3.The serum level of ICAM-1,IL-6increased after the MI(P<0.01);4. After the therapy of promoting blood circulation and removing blood stasis, we can observe the downward trend of serum creatinine and the upward trend of Ccr, but no significant difference(P>0.05). At the same time, the serum level of ICAM-1,IL-6slightly lower than model group, but no significant difference(P>0.05).
Conclusion
Kidney injuey could be observed after myocardial ischemia in hyperlipidemia rats, and the expression of inflammatory factors was increased. Promoting blood circulation therapy could reduce the degree of renal impairment caused by myocardial ischemia and reduce the level of TC and LDL-C.
引文
[1]C. Ronco, M. Haapio, A. A. House, et al. Cardiorenal syndrome [J]. Journal of the American College of Cardiology,2008,52(19):1527-1539.
[2]盖鲁粤,盖兢泾Roncc心肾综合征分型的病理生理学和临床意义[J].中国介入心脏病学杂志,2010,18(3)：172-175.
[3]Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin converting enzyme inhibition after myocardial infarction:the survival and ventricular enlargement (SAVE) study [J]. Circulation,2004,110(24):3667-3673.
[4]CR Parikh, SG Coca, Y Wang. Long-term prognosis of acute kidney injury after acute myocardial infarction[J]. Arch Intern Med,2008,168(9):987-95.
[5]P. Jose, H. Skali, N. Anavekar, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction[J]. Journal of the American Society of Nephrology,2006,17(10): 2886-2891.
[6]S. S. Gottlieb, W. Abraham, J. Butler, et al. The prognostic importance of different definitions of worsening renal function in congestive heart fai lure [J]. Journal of Cardiac Failure,2002,8(3):136-141.
[7]A. Goldberg, H. Hammerman, S. Petcherski, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction[J]. American Heart Journal,2005,150(2): 330-337.
[8]R. Latchamsetty, J. Fang, E. Kline-Rogers, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndromes [J]. American Journal of Cardiology,2007,99(7): 939-942.
[9]M. Metra, S. Nodari, G. Parrinello, et al. Worsening renal function in patients hospitalised for acute heart failure:clinical implications and prognostic significance[J]. European Journal of Heart Failure,2008,10(2):188-195.
[10]M. Metra, S. Nodari, G. Parrinello, et al. Worsening renal function in patients hospitalised for acute heart failure:clinical implications and prognostic significance [J]. European Journal of Heart Failure,2008,10(2): 188-195.
[11]D. E. Forman, J. Butler, Y. Wang, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure[J]. Journal of the American College of Cardiology,2004,43(1):61-67.
[12]Hillege HL, Nitsch D, PfefferMA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure[J]. Circulation,2006, 113(5):671-678.
[13]D. L. Dries, D. V. Exner, M. J. Domanski, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction[J]. Journal of the American College of Cardiology,2000,35(3):681-689.
[14]Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation,and survival in patients with chronic heart failure[J]. Circulation 2000,102(2):203-210.
[15]J. T. Heywood, G. C. Fonarow, M. R. Costanzo, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure:a report from the ADHERE Database [J]. Journal of Cardiac Failure,2007,13(6):422-430.
[16]E. F. Elsayed, H. Tighiouart, J. Griffith, et al. Cardiovascular disease and subsequent kidney disease [J]. Archives of Internal Medicine,2007,167(11): 1130-1136.
[17]A. K. Cheung, M. J. Sarnak, G. Yan, et al. Cardiac diseases in maintenance hemodialysis patients:results of the HEMO Study[J]. Kidney International,2004, 65(6):2380-2389.
[18]J.O. Burton, H. J. Jefferies, N. M. Selby, et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac funct ion [J]. Clinical Journal of the American Society of Nephrology,2009, 4(12):1925-1931.
[19]P. Muntner, J. He, L. Hamm, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States[J]. Journal of the American Society of Nephrology,2002,13(3):745-753.
[20]A. S. Go, G. M. Chertow, D. Fan, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization[J]. New England Journal of Medicine,2004,351(13):1296-1305.
[21]J. J. Grantham. Autosomal dominant polycystic kidney disease [J]. New England Journal of Medicine,2008,359(14):1477-1485.
[22]G. M. Fick, A. M. Johnson, W. S. Hammond, et al. Causes of death in autosomal dominant polycystic kidney disease [J]. Journal of the American Society of Nephrology,1995,5(12):2048-2056.
[23]W. E. Braun. Autosomal dominant polycyst ic kidney disease:emerging concepts of pathogenesis and new treatments [J]. Cleveland Clinic Journal of Medicine,2009, 76(2):97-104.
[24]Dinna N. Cruz, Sean M. Bagshaw. Heart-Kidney Interaction:Epidemiology of Cardiorenal Syndromes[J]. International Journal of Nephrology,2011, 2011(1):1-11.
[25]C. Geisberg and J. Butler. Addressing the challenges of cardiorenal syndrome[J]. Cleveland Clinic Journal of Medicine,2006,73(5):485-491.
[26]A. Nohria, V. Hasselblad, A. Stebbins et al. Cardiorenal interactions. Insights from the ESCAPE trial [J]. Journal of the American College of Cardiology, 2008,51(13):1268-1274.
[27]C. W. Yancy, M. Lopatin, L. W. Stevenson, T. de Marco, and G. C. Fonarow. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function:a report from the Acute Decompensated Heart Fai lure National Registry (ADHERE) database [J]. Journal of the American College of Cardiology,2006,47(1):76-84.
[28]Liu PP. Cardiorenal syndrome in heart failure:a cardiologist's perspective [J]. Can J Cardiol,2008,24 (suppl B):25B-29B.
[29]Brown JR, Uber PA, Mehra MR. The progressive cardiorenal syndrome in heart failure:mechanisms and therapeutic insights [J]. Curr Treat Options Cardiovasc Med,2008,10(4):342-348.
[30]Dzau VJ. Circulating versus local renin angiotensin system in cardiovascular homeostasis[J]. Circulation,1988,77 (6 pt2):14-13.
[31]Grazia M M,Fesc F,Pietro A,et al. Aldosterone inhibition limits collagen synthesis and progressive left venticular enlargement after anterior myocardial infarction[J]. Am Heart J,2001,141(1):41-6.
[32]Liu Y. Renal fibrosis:new insights into the pathogenesis and therapeutics [J]. Kidney Int,2006,69(2):213-217.
[33]David PB. The transforming growth factor beta system in kidney disease and repair:recent progress and future directions [J]. Curr Opin Nephrol Hy pertens, 1999,8(1):21-30.
[34]K. Leineweber, I. Heinroth-Hoffmann, K. P··onicke, G. Abraham, B. Osten, and 0. E. Brodde. Cardiac P-adrenoceptor desensitization due to increased β-adrenoceptor kinase activity in chronic uremia [J]. Journal of the American Society of Nephrology,2002,13(1):117-124.
[35]M. R. Bristow, R. Ginsburg, W. Minobe et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts[J]. New England Journal of Medicine,1982,307(4):205-211.
[36]G. Jackson, C. R. Gibbs, M. K. Davies, and G. Y. Lip. ABC of heart failure. Pathophysiology[J]. British Medical Journal,2000,320(7228):167-170.
[37]L. Li, E. W. Lee, H. Ji, and Z. Zukowska. Neuropeptide Y-induced acceleration of post angioplasty occlusion of rat carotid artery[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2003,23(7):1204-1210.
[38]Z. Zukowska-Grojec. Neuropeptide Y. A novel sympathetic stress hormone and more[J]. Annals of the New York Academy of Sciences,1995,29(771):219-33.
[39]H. Krum, M. Schlaich, R. Whitbourn et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study [J]. The Lancet,2009,373(9671):1275-1281,
[40]Tore-Amione G, Kapadia S, Benedict C, et al. Proinf lammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the Studies of n Ventricular Dysfunction (SOLVD)[J]. Am Coll Cardiol 1996,27(5): 1201-1206.
[41]Fan H, Sun B, Gu Q, et al. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart[J]. Am J Physiol Heart Circ Physiol,2002,282(5):1778-1786.
[42]Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients[J]. Hypertension 2000,18(9): 1207-1213
[43]Mitchell MD, Laird RE, Brown RD, et al. IL-beta stimulates rat cardiac f ibroblast migration via MAP kinase pathways [J]. Am J Physiol Heart C ire Physiol, 2007,29(2):1139-1147.
[44]Gurevitch J, Fmlkis I, Yuhas Y, et al. Antitumor necrosis factor-alpha improves myocardial recovery after is-chemia and reperfusion [J]. J Am Coil Cardiol,1997,30(6):1554-1561.
[45]Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative s tress and endothelial dysfunction by overexpression Of the angiotensin II type 1 receptor[J]. Circulation Research 2004,94(4):534-541.
[46]Deten A, Volz HC, Briest W, et al. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction [J]. Experimental studies in rats. Cardiovascular Research 2002,55(2):329-340.
[47]Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure[J]. J Am Coll Cardiol 2003,41(12):2164-2171.
[48]Kielstein J T, Bode-B..oger SM, Klein G, et al. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure [J]. Eur J Clin Invest,2003,33 (5):370-375.
[49]D. S. Silverberg, D. Wexler, M. Blum et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization[J]. Clinical Nephrology,2002,58(suppl 1):S37-S45.
[50]R. P. Silva, P. H. U. Barbosa,0. S. Kimura et al. Prevalance of anemia and its association with cardio-renal syndrome[J]. International Journal of Cardiology,2007,120(2):232-236.
[51]E.0'Meara, T. Clayton, M. B. McEntegart et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure—results of the candesartan in heart failure:assessment of reduction in mortality and morbidity (CHARM) program[J]. Circulation,2006,113(7):986-994.
[52]C. W. Yancy, M. Lopatin, L. W. Stevenson et al., "ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management and in-hospital outcomes of patients admitted with acute decompansated heart failure with preserved systolic function:a report from the Acute Decompansated Heart Failure National Registry (ADHERE) Database, " Journal of the American College of Cardiology, vol.47, pp.76-84,2006.
[53]M. R. Costanzo, J. T. Heywood, T. DeMarco et al., "Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure," Journal of the American College of Cardiology, vol.43, supplement 1, p. A180,2004.
[54]J. Bayliss, M. Norell, R. Canepa-Anson, G. Sutton, and P. Pole-Wilson, "Untreated heart failure:clinical and neuroendocrine effects of introducing diuretics," British Heart Journal, vol.57,no.1, pp.17-22,1987.
[55]Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart fai lure [J]. AmJ Med,1999,106 (1):90296.
[56]C. Geisberg and J. Butler, "Addressing the challenges of cardiorenal syndrome," Cleveland Clinic Journal of Medicine, vol.73, no.5, pp.485-491, 2006.
[57]G. Francis, "Acute decompensated heart failure:the cardiorenal syndrome, " Cleveland Clinic Journal of Medicine, vol.73, supplement 2, pp. S8-S13,2006.
[58]B. K. Kr··amer, F. Schweda, and G. A. J. Riegger, "Diuretic treatment and diuretic resistance in heart failure," American Journal of Medicine, vol.106, no.1, pp.90-96,1999.
[59]J. R. Oster, M. Epstein, and S. Smoller, "Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention," Annals of Internal Medicine, vol.99, no.3, pp.405-406,1983.
[60]C. Geisberg and J. Butler, "Addressing the challenges of cardiorenal syndrome," Cleveland Cl inic Journal of Medicine, vol.73, no.5, pp.485-491, 2006.
[61]D. Fliser, I. Zurbr··uggen, E.Mutschler et al., "Coadministration of albumin and furosemide in patients with the nephritic syndrome," Kidney International, vol.55, no.2, pp.629-634,1999.
[62]G.L. Bakris and M. R. Weir, " Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine:is this a cause for concern?" Archives of Internal Medicine, vol.160, no.5, pp.685-693,2000.
[63]M. Kittleson, S. Hurwitz, M. R. Shah et al., "Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality," Journal of the American College of Cardiology, vol.41, no.11, pp.2029-2035,2003.
[64]S. Yusuf, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure," The New England Journal of Medicine, vol.325, no.5, pp.293-302,1991.
[65]S. Ljungman, J. Kjekshus, and K. Swedberg, "Renal function in severe congestive heart failure during treatment with Enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] trial)," American Journal of Cardiology, vol.70, no.4, pp.479-487,1992.
[66]M. G. Shlipak, "Pharmacotherapy for heart failure in patients with renal insufficiency," Annals of Internal Medicine, vol.138, no.11, pp.917-924,2003.
[67]J. Butler, D. E. Forraan, W. T. Abraham et al., "Relat ionship between heart failure treatment and development of worsening renal function among hospitalized patients," American Heart Journal, vol.147, no.2, pp.331-338,2004.
[68]P.Marik, "Low-dose dopamine:a systematic review, " Intens ive Care Medicine, vol.28, no.7, pp.877-883,2002.
[69]A. Lauschke, U. Teichgr··aber, U. Frei, and K.-U. Eckardt, "'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure," Kidney International, vol.69, no.9, pp.1669-1674,2006.
[70]M. Lainscak, A. P. Coletta, N. Sherwi, and J. G. F. Cleland, "Clinical trials update from the Heart Failure Society of America Meeting 2009:FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1, " European Journal of Heart Failure, vol.12, no.2, pp.193-196,2010.
[71]U. Elkayam, G. Tasissa, C. Binanay et al., "Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure, " American Heart Journal, vol.153, no. 1,pp.98-104,2007.
[72]G. M. Felker and C. M.0'Connor, "Inotropic therapy for heart failure:an evidence-based approach, " American Heart Journal, vol.142, no.3, pp.393-401, 2001.
[73]L. Lehtonen, "Levosimendan:a calcium-sensitizing agent for the treatment of patients with decompensated heart failure," Current Heart Failure Reports, vol.1, no.3, pp.136-144,2004.
[74]R. A. Zager, A. C. Johnson, S. Lund, S. Y. Hanson, and C. L Abrass, "Levosimendan protects against experimental endotoxemic acute renal failure," American Journal of Physiology, vol.290, no.6, pp. F1453-F1462,2006.
[75]P. P. Liu, "Cardiorenal syndrome in heart failure:a cardiologist's perspective," Canadian Journal of Cardiology, vol.24, supplement, pp.25B-29B, 2008.
[76]L. S. Marcus, D. Hart, M. Packer et al., "Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure:a doubleblind, placebo-controlled, randomized crossover trial," Circulation, vol.94, no.12, pp.3184-3189,1996.
[77]W. T. Abraham, B. D. Lowes, D. A. Ferguson et al., "Systemic hemodynamic, neurohormonal, and renal effects of a steadystate infusion of human brain natr iuretic pep tide in patients with hemodynamical ly decompensated heart fai lure, " Journal of Cardiac Failure, vol.4, no.1, pp.37-44,1998.
[78]D. J. Wang, T. C. Dowling, D. Meadows et al., "Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine," Circulation, vol.110, no.12, pp.1620-1625,2004.
[79]J. B. Young, "Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial, " Journal of the American Medical Association, vol.287, no.12, pp.1531-1540,2002.
[80]G. Marenzi, G. Lauri, M. Grazi, E. Assanelli, J. Campodonico, and P. Agostoni, " Circulatory response to fluid overload removal by extracorporeal ultraf iltration in refractory congestive heart failure, " Journal of the American College of Cardiology, vol.38, no.4, pp.963-968,2001.
[81]M. R. Costanzo, M. E. Guglin, M. T. Saltzberg et al., "Ultraf iltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure," Journal of the American College of Cardiology, vol.49, no.6, pp. 675-683,2007.
[82]S. Nielsen, C.-L. Chou, D. Marples, E. I. Christensen, B. L Kishore, and M. A. Knepper, "Vasopressin increases water permeability of kidney collecting duct by inducing translocat ion of aquaporin-CD water channels to plasma membrane, " Proceedings of the National Academy of Sciences of the United States of America, vol.92, no.4, pp.1013-1017,1995.
[83]M. Gheorghiade, W. A. Gattis, C. M.0'Connor et al., "Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized control led trial, " Journal of the American Medical Association, vol. 291, no.16, pp.1963-1971,2004.
[84]M. H. Drazner, J. E. Rame, L. W. Stevenson, and D. L. Dries, "Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure, " New England Journal of Medicine, vol.345, no.8, pp. 574-581,2001.
[85]D. S. Silverberg, D.Wexler,M. Blumetal., "The correct ion of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization," Clinical Nephrology, vol.58, pp. S37-S45,2002.
[86]S. S. Gottlieb, D. C. Brater, I. Thomas et al., "BG9719 (CVT-124), an Al adenosine receptor antagonist, protects against the decline in renal function observed wi th diuretic therapy, " Circulation, vol.105, no.11, pp.1348-1353, 2002.
[87]B. D. Weatherley, G. Cotter, H. C. Di ttrich et al., "Design and rat ionale of the PROTECT study:a placebo-controlled randomized study of the selective Al adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function," Journal of Cardiac Failure, vol.16, no.1, pp. 25-35,2010.
[88]S. S. Gottlieb, M. M. Givertz, M. Metra et al., "The effects of adenosine Al receptor antagonism in patients with acute decompensated heart failure and worsening renal function:the REACH UP study," Journal of Cardiac Failure, vol. 16, no.9, pp.714-719,2010.
[89]S. D. Anker, J. C. Colet, G. Filippatos et al., "Ferric carboxymaltose in pat ients with heart fai lure and iron deficiency, " New England Journal of Medicine, vol.361, no.25, pp.2436-2448,2009.
[90]L. Calvillo, R. Latini, J. Kajstura et al., "Recombinant human erythropoietin protects the myocardium from ischemiareperfusion injury and promotes beneficial remodeling, " Proceedings of the National Academy of Sciences of the United States of America, vol.100, no.8, pp.4802-4806,2003.
[91]C. J. Parsa, A. Matsumoto, J. Kim et al., "A novel protective effect of erythropoietin in the infarcted heart, " Journal of Clinical Investigation, vol. 112, no.7, pp.999-1007,2003.
[92]D. Burger, M. Lei, N. Geoghegan-Morphet, X. Lu, A. Xenocostas, and Q. Feng, "Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitrie oxide synthase," Cardiovascular Research, vol.72, no. 1,pp. 51-59,2006.
[93]D. M. Mancini, S. D. Katz, C. C. Lang, J. LaManca, A. Hudaihed, and A. S. Androne, "Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure," Circulation, vol.107, no.2, pp.294-299, 2003.
[94]P. van der Meer, D. J. Lok, J. L. Januzzi et al., "Adequacy of endogenous erythropoietin levels and mortality inanaemic heart failure patients, " European Heart Journal, vol.29, no.12, pp.1510-1515,2008.
[95]T. B. Drueke, F. Locatelli, N. Clyne et al., "Normalization of haemoglobin level in patients with chronic kidney disease and anaemia, " New England Journal ofMedicine, vol.355, pp.2071-2084,2006.
[96]M. A. Pfeffer, E. A. Burdmann, C. Y. Chen et al., "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease," New England Journal of Medicine, vol.361, no.21, pp.2019-2032,2009.
[97]A. K. Singh, L. Szczech, K. L. Tang et al., "Correction of anemia with epoetin alfa in chronic kidney disease," New England Journal of Medicine, vol.355, no. 20, pp.2085-2098,2006.
[98]D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal et al., "Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart fai lure and anaemia, " European Heart Journal, vol.28, no.18, pp.2208-2216,2007.
[1]尹柱汉,陈冰. 从脏腑虚实论治高脂血症[J]. 时珍国医国药,2001,12(6)：551.
[2]丁邦晗,严夏,林晓忠等.血脂异常与胸痹心痛基本证型的相关性分析一365例病例资料Logistic回归分析结果[J]. 辽宁中医杂志,2006,33(10)：1261-1262.
[3]邱一真.辛伐他汀联合参麦治疗高血脂症的疗效观察[J].实用中西医结合临床,2010,10(6)：9.
[4]扶桂升.小陷胸汤合丹参饮治疗高脂血症痰瘀互结证的临床观察[J].中国中医药现代远程教育,2008,6(5)：469-470.
[5]毛炜,江巍,陈可冀.小陷胸汤加味对实验性高脂血症大鼠血脂的影响[J].时珍国医国药,2010,21(12)：3360-3361.
[6]吴水盛,张丽霞.补阳还五汤加减治疗高脂血症疗效观察[J].中华中医药学刊,2007,25(1)：31-32.
[7]徐淑敏.补阳还五汤加味治疗高血脂症[J].吉林中医药,2005,25(10)：17.
[8]黄宪章,金卓祥,任燕歌等.补阳还五汤加减治疗冠心病对血脂和雌二醇代谢的影响[J].循环学杂志,2007,17(3)：29-30.
[9]宋春晖,李丽.温胆汤加减治疗高脂血症60例[J].江西中医药,2006,37(6)：53.
[10]姚红,李阳,孙飞.从痰瘀论治高脂血症119例分析[J].实用中医内科杂志,2004,18(1)：40-41.
[11]武晓宇,王燕,马伯艳等.温胆汤对实验性大鼠血脂代谢紊乱的调节及机理研究[J],中国实验方剂学杂志,2007,13(7)：44-46.
[12]孙素芹.越鞠丸加减治疗高脂血症44例临床观察[J].上海中医药杂志,2008,42(1)：35-36.
[13]邓国兴,张金兰,高玮等.鞠丸对非酒精性脂肪肝病大鼠肝脏PPAR a表达影响[J].中国老年学杂志,2011, (07)：1219-1220.
[14]张双贵.血府逐瘀汤加减治疗高脂血症58例[J].湖南中医杂志2008,24(4)：52-53.
[15]刘磊,李川,唐姬.血府逐瘀汤治疗老年原发性高脂血症60例疗效观察[J],2010,12(5)：330-332.
[16]潘丰满,桂壮.二陈汤加味治疗高血症性非酒精性脂肪性肝病42例[J].长江大学学报(自然科学版).2010,7(4)：13-14.
[17]刘海军.自拟降脂汤治疗高脂血症临床疗效观察[J].光明中医.2012,27(2)261-261.
[18]杨宗强.自拟降脂散治疗高脂血症50临床例疗效观察[J].中国民族民间医药.2012,(02)：88.
[19]王继合.助阳化气法治疗高脂血症60例疗效观察[J].河北中医.2011,33(11)：1641-1642.
[20]朱存建,刘洪峰.芪葛降脂汤加减治疗高脂血症60例临床观察[J].四川中医,2012,30(2)：84-85.
[21]单春妹,陈谭升.补肾化浊法治疗老年高血脂症的体会[J].现代中西医结合杂志,2009,(22)：2698-2702.
[22]杨仕彬,党庆先.中西医结合治疗高脂血症疗效观察[J].实用中医药杂志.2006,22(1)：17-18.
[23]赵顺利,高诗云,杜昊.降脂益肝汤治疗高脂血症疗效观察[J].人民军医,2012,55(1)：39-40.
[24]张娜.茵陈五苓散加味治疗糖尿病高脂血症[J].湖北中医杂志,2011,33(12)：28.
[25]叶志兵,刘树人.加味大柴胡汤治疗脂肪肝37例疗效观察[J].新中医.2007,39(12)：86-87.
[26]熊文生,曾益宏,刘友章等.理脾化痰降脂片治疗老年高脂血症140例疗效观察[J].新中医,2000,32(7)：16-18.
[27]郑萍红,李飞泽,杨朔.益气调脂颗粒治疗高脂血症72例临床观察[J].浙江中医杂志,2011,46(12)：886-887.
[28]王巍.调脂活络方对高脂血症的影响[J].河北中医,2011,33(12)：1784-1785.
[29]张万祥,林竹.中医药治疗高血脂研究进展[J].甘肃中医,2006,19(12)：47-49.
[30]顾翔华.高脂血症的中医药研究进展[J].湖北中医杂志,2010,32(9)：76-78.
[31]吴红军,傅莉萍,王瑞华.穴位注射治疗高脂血症疗效观察[J].上海针灸杂志,2005,24(8)：26-27.
[32]陈太福.三阴交为主针刺治疗单纯性高脂血症[J].黑龙江中医药,2003,10(1)：43-44.
[33]张唐法,万文俊,张红星等.电针丰隆穴治疗高脂血症的多中心观察[J].中国临床康复,2006,10(19)：17-19.
[34]周喜燕,李滨.针灸治疗痰浊血瘀型高脂血症50例[J].吉林中医药,2005,25(6)：39.
[35]俞文全,许祥贵,吴焕淦.针灸治疗高脂血症的临床研究[J].上海针灸杂志.2011,30(3)：155-157.
[36]老锦雄,潘清洁.温针灸对冠心病血瘀证患者血脂及血液流变学的干预研究[J].上海针灸杂志,2011,30(10)：656-658.
[37]王国明,沈玲哲,温峰云等.瘢痕灸治疗高脂血症40例临床观察[J].中国中医药信息杂志,2000,11(7)：72-73.
[38]黄华超.艾柱灸治疗高脂血症65例[J].实用中医药杂志,2010,26(7)：494-495.
[1]尹倪,陈胜喜,罗万俊等.冠状动脉前降支结扎法制作大鼠急性心肌梗死模型[J].中国医师杂志,2006,8(9)：1193-1195.
[2]孙波,高海成,黄秀英等.冠脉结扎法与给药法制做大鼠心肌缺血模型的比较[J].实验动物学,2010,27(5)：16-18.
[3]陈大宇.内生肌酐清除率测定在肾脏疾病中的应用[J].华夏医学,2010,4(14)：454-455.
[4]IkataJ, Wakatsuki T, Oishi Y, et al. Leukocyte counts and concentration of soluble ashesion molecules as predictors of coronary atherogenesis [J]. Coron Artery Dis.2000,11(6): 445.
[5]Pilar A, Manel S. Tubular and Interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy Am J Nephrol,2003,23:121-128.
[6]Jenny NS, Tracy RP, OggMS, et al. In the eldely, interleukin-6 plasma levels and the polymorphism are associated with the development of cardiovascular disease [J]. Arterioscler Thromb vase Boil,2002,22 (12):2066-2071.
[2]盖鲁粤,盖兢泾Roncc心肾综合征分型的病理生理学和临床意义[J].中国介入心脏病学杂志,2010,18(3)：172-175.
[3]Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin converting enzyme inhibition after myocardial infarction:the survival and ventricular enlargement (SAVE) study [J]. Circulation,2004,110(24):3667-3673.
[4]CR Parikh, SG Coca, Y Wang. Long-term prognosis of acute kidney injury after acute myocardial infarction[J]. Arch Intern Med,2008,168(9):987-95.
[5]P. Jose, H. Skali, N. Anavekar, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction[J]. Journal of the American Society of Nephrology,2006,17(10): 2886-2891.
[6]S. S. Gottlieb, W. Abraham, J. Butler, et al. The prognostic importance of different definitions of worsening renal function in congestive heart fai lure [J]. Journal of Cardiac Failure,2002,8(3):136-141.
[7]A. Goldberg, H. Hammerman, S. Petcherski, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction[J]. American Heart Journal,2005,150(2): 330-337.
[8]R. Latchamsetty, J. Fang, E. Kline-Rogers, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndromes [J]. American Journal of Cardiology,2007,99(7): 939-942.
[9]M. Metra, S. Nodari, G. Parrinello, et al. Worsening renal function in patients hospitalised for acute heart failure:clinical implications and prognostic significance[J]. European Journal of Heart Failure,2008,10(2):188-195.
[10]M. Metra, S. Nodari, G. Parrinello, et al. Worsening renal function in patients hospitalised for acute heart failure:clinical implications and prognostic significance [J]. European Journal of Heart Failure,2008,10(2): 188-195.
[11]D. E. Forman, J. Butler, Y. Wang, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure[J]. Journal of the American College of Cardiology,2004,43(1):61-67.
[12]Hillege HL, Nitsch D, PfefferMA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure[J]. Circulation,2006, 113(5):671-678.
[13]D. L. Dries, D. V. Exner, M. J. Domanski, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction[J]. Journal of the American College of Cardiology,2000,35(3):681-689.
[14]Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation,and survival in patients with chronic heart failure[J]. Circulation 2000,102(2):203-210.
[15]J. T. Heywood, G. C. Fonarow, M. R. Costanzo, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure:a report from the ADHERE Database [J]. Journal of Cardiac Failure,2007,13(6):422-430.
[16]E. F. Elsayed, H. Tighiouart, J. Griffith, et al. Cardiovascular disease and subsequent kidney disease [J]. Archives of Internal Medicine,2007,167(11): 1130-1136.
[17]A. K. Cheung, M. J. Sarnak, G. Yan, et al. Cardiac diseases in maintenance hemodialysis patients:results of the HEMO Study[J]. Kidney International,2004, 65(6):2380-2389.
[18]J.O. Burton, H. J. Jefferies, N. M. Selby, et al. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac funct ion [J]. Clinical Journal of the American Society of Nephrology,2009, 4(12):1925-1931.
[19]P. Muntner, J. He, L. Hamm, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States[J]. Journal of the American Society of Nephrology,2002,13(3):745-753.
[20]A. S. Go, G. M. Chertow, D. Fan, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization[J]. New England Journal of Medicine,2004,351(13):1296-1305.
[21]J. J. Grantham. Autosomal dominant polycystic kidney disease [J]. New England Journal of Medicine,2008,359(14):1477-1485.
[22]G. M. Fick, A. M. Johnson, W. S. Hammond, et al. Causes of death in autosomal dominant polycystic kidney disease [J]. Journal of the American Society of Nephrology,1995,5(12):2048-2056.
[23]W. E. Braun. Autosomal dominant polycyst ic kidney disease:emerging concepts of pathogenesis and new treatments [J]. Cleveland Clinic Journal of Medicine,2009, 76(2):97-104.
[24]Dinna N. Cruz, Sean M. Bagshaw. Heart-Kidney Interaction:Epidemiology of Cardiorenal Syndromes[J]. International Journal of Nephrology,2011, 2011(1):1-11.
[25]C. Geisberg and J. Butler. Addressing the challenges of cardiorenal syndrome[J]. Cleveland Clinic Journal of Medicine,2006,73(5):485-491.
[26]A. Nohria, V. Hasselblad, A. Stebbins et al. Cardiorenal interactions. Insights from the ESCAPE trial [J]. Journal of the American College of Cardiology, 2008,51(13):1268-1274.
[27]C. W. Yancy, M. Lopatin, L. W. Stevenson, T. de Marco, and G. C. Fonarow. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function:a report from the Acute Decompensated Heart Fai lure National Registry (ADHERE) database [J]. Journal of the American College of Cardiology,2006,47(1):76-84.
[28]Liu PP. Cardiorenal syndrome in heart failure:a cardiologist's perspective [J]. Can J Cardiol,2008,24 (suppl B):25B-29B.
[29]Brown JR, Uber PA, Mehra MR. The progressive cardiorenal syndrome in heart failure:mechanisms and therapeutic insights [J]. Curr Treat Options Cardiovasc Med,2008,10(4):342-348.
[30]Dzau VJ. Circulating versus local renin angiotensin system in cardiovascular homeostasis[J]. Circulation,1988,77 (6 pt2):14-13.
[31]Grazia M M,Fesc F,Pietro A,et al. Aldosterone inhibition limits collagen synthesis and progressive left venticular enlargement after anterior myocardial infarction[J]. Am Heart J,2001,141(1):41-6.
[32]Liu Y. Renal fibrosis:new insights into the pathogenesis and therapeutics [J]. Kidney Int,2006,69(2):213-217.
[33]David PB. The transforming growth factor beta system in kidney disease and repair:recent progress and future directions [J]. Curr Opin Nephrol Hy pertens, 1999,8(1):21-30.
[34]K. Leineweber, I. Heinroth-Hoffmann, K. P··onicke, G. Abraham, B. Osten, and 0. E. Brodde. Cardiac P-adrenoceptor desensitization due to increased β-adrenoceptor kinase activity in chronic uremia [J]. Journal of the American Society of Nephrology,2002,13(1):117-124.
[35]M. R. Bristow, R. Ginsburg, W. Minobe et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts[J]. New England Journal of Medicine,1982,307(4):205-211.
[36]G. Jackson, C. R. Gibbs, M. K. Davies, and G. Y. Lip. ABC of heart failure. Pathophysiology[J]. British Medical Journal,2000,320(7228):167-170.
[37]L. Li, E. W. Lee, H. Ji, and Z. Zukowska. Neuropeptide Y-induced acceleration of post angioplasty occlusion of rat carotid artery[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2003,23(7):1204-1210.
[38]Z. Zukowska-Grojec. Neuropeptide Y. A novel sympathetic stress hormone and more[J]. Annals of the New York Academy of Sciences,1995,29(771):219-33.
[39]H. Krum, M. Schlaich, R. Whitbourn et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study [J]. The Lancet,2009,373(9671):1275-1281,
[40]Tore-Amione G, Kapadia S, Benedict C, et al. Proinf lammatory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the Studies of n Ventricular Dysfunction (SOLVD)[J]. Am Coll Cardiol 1996,27(5): 1201-1206.
[41]Fan H, Sun B, Gu Q, et al. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart[J]. Am J Physiol Heart Circ Physiol,2002,282(5):1778-1786.
[42]Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients[J]. Hypertension 2000,18(9): 1207-1213
[43]Mitchell MD, Laird RE, Brown RD, et al. IL-beta stimulates rat cardiac f ibroblast migration via MAP kinase pathways [J]. Am J Physiol Heart C ire Physiol, 2007,29(2):1139-1147.
[44]Gurevitch J, Fmlkis I, Yuhas Y, et al. Antitumor necrosis factor-alpha improves myocardial recovery after is-chemia and reperfusion [J]. J Am Coil Cardiol,1997,30(6):1554-1561.
[45]Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative s tress and endothelial dysfunction by overexpression Of the angiotensin II type 1 receptor[J]. Circulation Research 2004,94(4):534-541.
[46]Deten A, Volz HC, Briest W, et al. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction [J]. Experimental studies in rats. Cardiovascular Research 2002,55(2):329-340.
[47]Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure[J]. J Am Coll Cardiol 2003,41(12):2164-2171.
[48]Kielstein J T, Bode-B..oger SM, Klein G, et al. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure [J]. Eur J Clin Invest,2003,33 (5):370-375.
[49]D. S. Silverberg, D. Wexler, M. Blum et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization[J]. Clinical Nephrology,2002,58(suppl 1):S37-S45.
[50]R. P. Silva, P. H. U. Barbosa,0. S. Kimura et al. Prevalance of anemia and its association with cardio-renal syndrome[J]. International Journal of Cardiology,2007,120(2):232-236.
[51]E.0'Meara, T. Clayton, M. B. McEntegart et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure—results of the candesartan in heart failure:assessment of reduction in mortality and morbidity (CHARM) program[J]. Circulation,2006,113(7):986-994.
[52]C. W. Yancy, M. Lopatin, L. W. Stevenson et al., "ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management and in-hospital outcomes of patients admitted with acute decompansated heart failure with preserved systolic function:a report from the Acute Decompansated Heart Failure National Registry (ADHERE) Database, " Journal of the American College of Cardiology, vol.47, pp.76-84,2006.
[53]M. R. Costanzo, J. T. Heywood, T. DeMarco et al., "Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure," Journal of the American College of Cardiology, vol.43, supplement 1, p. A180,2004.
[54]J. Bayliss, M. Norell, R. Canepa-Anson, G. Sutton, and P. Pole-Wilson, "Untreated heart failure:clinical and neuroendocrine effects of introducing diuretics," British Heart Journal, vol.57,no.1, pp.17-22,1987.
[55]Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart fai lure [J]. AmJ Med,1999,106 (1):90296.
[56]C. Geisberg and J. Butler, "Addressing the challenges of cardiorenal syndrome," Cleveland Clinic Journal of Medicine, vol.73, no.5, pp.485-491, 2006.
[57]G. Francis, "Acute decompensated heart failure:the cardiorenal syndrome, " Cleveland Clinic Journal of Medicine, vol.73, supplement 2, pp. S8-S13,2006.
[58]B. K. Kr··amer, F. Schweda, and G. A. J. Riegger, "Diuretic treatment and diuretic resistance in heart failure," American Journal of Medicine, vol.106, no.1, pp.90-96,1999.
[59]J. R. Oster, M. Epstein, and S. Smoller, "Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention," Annals of Internal Medicine, vol.99, no.3, pp.405-406,1983.
[60]C. Geisberg and J. Butler, "Addressing the challenges of cardiorenal syndrome," Cleveland Cl inic Journal of Medicine, vol.73, no.5, pp.485-491, 2006.
[61]D. Fliser, I. Zurbr··uggen, E.Mutschler et al., "Coadministration of albumin and furosemide in patients with the nephritic syndrome," Kidney International, vol.55, no.2, pp.629-634,1999.
[62]G.L. Bakris and M. R. Weir, " Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine:is this a cause for concern?" Archives of Internal Medicine, vol.160, no.5, pp.685-693,2000.
[63]M. Kittleson, S. Hurwitz, M. R. Shah et al., "Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality," Journal of the American College of Cardiology, vol.41, no.11, pp.2029-2035,2003.
[64]S. Yusuf, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure," The New England Journal of Medicine, vol.325, no.5, pp.293-302,1991.
[65]S. Ljungman, J. Kjekshus, and K. Swedberg, "Renal function in severe congestive heart failure during treatment with Enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] trial)," American Journal of Cardiology, vol.70, no.4, pp.479-487,1992.
[66]M. G. Shlipak, "Pharmacotherapy for heart failure in patients with renal insufficiency," Annals of Internal Medicine, vol.138, no.11, pp.917-924,2003.
[67]J. Butler, D. E. Forraan, W. T. Abraham et al., "Relat ionship between heart failure treatment and development of worsening renal function among hospitalized patients," American Heart Journal, vol.147, no.2, pp.331-338,2004.
[68]P.Marik, "Low-dose dopamine:a systematic review, " Intens ive Care Medicine, vol.28, no.7, pp.877-883,2002.
[69]A. Lauschke, U. Teichgr··aber, U. Frei, and K.-U. Eckardt, "'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure," Kidney International, vol.69, no.9, pp.1669-1674,2006.
[70]M. Lainscak, A. P. Coletta, N. Sherwi, and J. G. F. Cleland, "Clinical trials update from the Heart Failure Society of America Meeting 2009:FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1, " European Journal of Heart Failure, vol.12, no.2, pp.193-196,2010.
[71]U. Elkayam, G. Tasissa, C. Binanay et al., "Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure, " American Heart Journal, vol.153, no. 1,pp.98-104,2007.
[72]G. M. Felker and C. M.0'Connor, "Inotropic therapy for heart failure:an evidence-based approach, " American Heart Journal, vol.142, no.3, pp.393-401, 2001.
[73]L. Lehtonen, "Levosimendan:a calcium-sensitizing agent for the treatment of patients with decompensated heart failure," Current Heart Failure Reports, vol.1, no.3, pp.136-144,2004.
[74]R. A. Zager, A. C. Johnson, S. Lund, S. Y. Hanson, and C. L Abrass, "Levosimendan protects against experimental endotoxemic acute renal failure," American Journal of Physiology, vol.290, no.6, pp. F1453-F1462,2006.
[75]P. P. Liu, "Cardiorenal syndrome in heart failure:a cardiologist's perspective," Canadian Journal of Cardiology, vol.24, supplement, pp.25B-29B, 2008.
[76]L. S. Marcus, D. Hart, M. Packer et al., "Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure:a doubleblind, placebo-controlled, randomized crossover trial," Circulation, vol.94, no.12, pp.3184-3189,1996.
[77]W. T. Abraham, B. D. Lowes, D. A. Ferguson et al., "Systemic hemodynamic, neurohormonal, and renal effects of a steadystate infusion of human brain natr iuretic pep tide in patients with hemodynamical ly decompensated heart fai lure, " Journal of Cardiac Failure, vol.4, no.1, pp.37-44,1998.
[78]D. J. Wang, T. C. Dowling, D. Meadows et al., "Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine," Circulation, vol.110, no.12, pp.1620-1625,2004.
[79]J. B. Young, "Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial, " Journal of the American Medical Association, vol.287, no.12, pp.1531-1540,2002.
[80]G. Marenzi, G. Lauri, M. Grazi, E. Assanelli, J. Campodonico, and P. Agostoni, " Circulatory response to fluid overload removal by extracorporeal ultraf iltration in refractory congestive heart failure, " Journal of the American College of Cardiology, vol.38, no.4, pp.963-968,2001.
[81]M. R. Costanzo, M. E. Guglin, M. T. Saltzberg et al., "Ultraf iltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure," Journal of the American College of Cardiology, vol.49, no.6, pp. 675-683,2007.
[82]S. Nielsen, C.-L. Chou, D. Marples, E. I. Christensen, B. L Kishore, and M. A. Knepper, "Vasopressin increases water permeability of kidney collecting duct by inducing translocat ion of aquaporin-CD water channels to plasma membrane, " Proceedings of the National Academy of Sciences of the United States of America, vol.92, no.4, pp.1013-1017,1995.
[83]M. Gheorghiade, W. A. Gattis, C. M.0'Connor et al., "Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized control led trial, " Journal of the American Medical Association, vol. 291, no.16, pp.1963-1971,2004.
[84]M. H. Drazner, J. E. Rame, L. W. Stevenson, and D. L. Dries, "Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure, " New England Journal of Medicine, vol.345, no.8, pp. 574-581,2001.
[85]D. S. Silverberg, D.Wexler,M. Blumetal., "The correct ion of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization," Clinical Nephrology, vol.58, pp. S37-S45,2002.
[86]S. S. Gottlieb, D. C. Brater, I. Thomas et al., "BG9719 (CVT-124), an Al adenosine receptor antagonist, protects against the decline in renal function observed wi th diuretic therapy, " Circulation, vol.105, no.11, pp.1348-1353, 2002.
[87]B. D. Weatherley, G. Cotter, H. C. Di ttrich et al., "Design and rat ionale of the PROTECT study:a placebo-controlled randomized study of the selective Al adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function," Journal of Cardiac Failure, vol.16, no.1, pp. 25-35,2010.
[88]S. S. Gottlieb, M. M. Givertz, M. Metra et al., "The effects of adenosine Al receptor antagonism in patients with acute decompensated heart failure and worsening renal function:the REACH UP study," Journal of Cardiac Failure, vol. 16, no.9, pp.714-719,2010.
[89]S. D. Anker, J. C. Colet, G. Filippatos et al., "Ferric carboxymaltose in pat ients with heart fai lure and iron deficiency, " New England Journal of Medicine, vol.361, no.25, pp.2436-2448,2009.
[90]L. Calvillo, R. Latini, J. Kajstura et al., "Recombinant human erythropoietin protects the myocardium from ischemiareperfusion injury and promotes beneficial remodeling, " Proceedings of the National Academy of Sciences of the United States of America, vol.100, no.8, pp.4802-4806,2003.
[91]C. J. Parsa, A. Matsumoto, J. Kim et al., "A novel protective effect of erythropoietin in the infarcted heart, " Journal of Clinical Investigation, vol. 112, no.7, pp.999-1007,2003.
[92]D. Burger, M. Lei, N. Geoghegan-Morphet, X. Lu, A. Xenocostas, and Q. Feng, "Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitrie oxide synthase," Cardiovascular Research, vol.72, no. 1,pp. 51-59,2006.
[93]D. M. Mancini, S. D. Katz, C. C. Lang, J. LaManca, A. Hudaihed, and A. S. Androne, "Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure," Circulation, vol.107, no.2, pp.294-299, 2003.
[94]P. van der Meer, D. J. Lok, J. L. Januzzi et al., "Adequacy of endogenous erythropoietin levels and mortality inanaemic heart failure patients, " European Heart Journal, vol.29, no.12, pp.1510-1515,2008.
[95]T. B. Drueke, F. Locatelli, N. Clyne et al., "Normalization of haemoglobin level in patients with chronic kidney disease and anaemia, " New England Journal ofMedicine, vol.355, pp.2071-2084,2006.
[96]M. A. Pfeffer, E. A. Burdmann, C. Y. Chen et al., "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease," New England Journal of Medicine, vol.361, no.21, pp.2019-2032,2009.
[97]A. K. Singh, L. Szczech, K. L. Tang et al., "Correction of anemia with epoetin alfa in chronic kidney disease," New England Journal of Medicine, vol.355, no. 20, pp.2085-2098,2006.
[98]D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal et al., "Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart fai lure and anaemia, " European Heart Journal, vol.28, no.18, pp.2208-2216,2007.
[1]尹柱汉,陈冰. 从脏腑虚实论治高脂血症[J]. 时珍国医国药,2001,12(6)：551.
[2]丁邦晗,严夏,林晓忠等.血脂异常与胸痹心痛基本证型的相关性分析一365例病例资料Logistic回归分析结果[J]. 辽宁中医杂志,2006,33(10)：1261-1262.
[3]邱一真.辛伐他汀联合参麦治疗高血脂症的疗效观察[J].实用中西医结合临床,2010,10(6)：9.
[4]扶桂升.小陷胸汤合丹参饮治疗高脂血症痰瘀互结证的临床观察[J].中国中医药现代远程教育,2008,6(5)：469-470.
[5]毛炜,江巍,陈可冀.小陷胸汤加味对实验性高脂血症大鼠血脂的影响[J].时珍国医国药,2010,21(12)：3360-3361.
[6]吴水盛,张丽霞.补阳还五汤加减治疗高脂血症疗效观察[J].中华中医药学刊,2007,25(1)：31-32.
[7]徐淑敏.补阳还五汤加味治疗高血脂症[J].吉林中医药,2005,25(10)：17.
[8]黄宪章,金卓祥,任燕歌等.补阳还五汤加减治疗冠心病对血脂和雌二醇代谢的影响[J].循环学杂志,2007,17(3)：29-30.
[9]宋春晖,李丽.温胆汤加减治疗高脂血症60例[J].江西中医药,2006,37(6)：53.
[10]姚红,李阳,孙飞.从痰瘀论治高脂血症119例分析[J].实用中医内科杂志,2004,18(1)：40-41.
[11]武晓宇,王燕,马伯艳等.温胆汤对实验性大鼠血脂代谢紊乱的调节及机理研究[J],中国实验方剂学杂志,2007,13(7)：44-46.
[12]孙素芹.越鞠丸加减治疗高脂血症44例临床观察[J].上海中医药杂志,2008,42(1)：35-36.
[13]邓国兴,张金兰,高玮等.鞠丸对非酒精性脂肪肝病大鼠肝脏PPAR a表达影响[J].中国老年学杂志,2011, (07)：1219-1220.
[14]张双贵.血府逐瘀汤加减治疗高脂血症58例[J].湖南中医杂志2008,24(4)：52-53.
[15]刘磊,李川,唐姬.血府逐瘀汤治疗老年原发性高脂血症60例疗效观察[J],2010,12(5)：330-332.
[16]潘丰满,桂壮.二陈汤加味治疗高血症性非酒精性脂肪性肝病42例[J].长江大学学报(自然科学版).2010,7(4)：13-14.
[17]刘海军.自拟降脂汤治疗高脂血症临床疗效观察[J].光明中医.2012,27(2)261-261.
[18]杨宗强.自拟降脂散治疗高脂血症50临床例疗效观察[J].中国民族民间医药.2012,(02)：88.
[19]王继合.助阳化气法治疗高脂血症60例疗效观察[J].河北中医.2011,33(11)：1641-1642.
[20]朱存建,刘洪峰.芪葛降脂汤加减治疗高脂血症60例临床观察[J].四川中医,2012,30(2)：84-85.
[21]单春妹,陈谭升.补肾化浊法治疗老年高血脂症的体会[J].现代中西医结合杂志,2009,(22)：2698-2702.
[22]杨仕彬,党庆先.中西医结合治疗高脂血症疗效观察[J].实用中医药杂志.2006,22(1)：17-18.
[23]赵顺利,高诗云,杜昊.降脂益肝汤治疗高脂血症疗效观察[J].人民军医,2012,55(1)：39-40.
[24]张娜.茵陈五苓散加味治疗糖尿病高脂血症[J].湖北中医杂志,2011,33(12)：28.
[25]叶志兵,刘树人.加味大柴胡汤治疗脂肪肝37例疗效观察[J].新中医.2007,39(12)：86-87.
[26]熊文生,曾益宏,刘友章等.理脾化痰降脂片治疗老年高脂血症140例疗效观察[J].新中医,2000,32(7)：16-18.
[27]郑萍红,李飞泽,杨朔.益气调脂颗粒治疗高脂血症72例临床观察[J].浙江中医杂志,2011,46(12)：886-887.
[28]王巍.调脂活络方对高脂血症的影响[J].河北中医,2011,33(12)：1784-1785.
[29]张万祥,林竹.中医药治疗高血脂研究进展[J].甘肃中医,2006,19(12)：47-49.
[30]顾翔华.高脂血症的中医药研究进展[J].湖北中医杂志,2010,32(9)：76-78.
[31]吴红军,傅莉萍,王瑞华.穴位注射治疗高脂血症疗效观察[J].上海针灸杂志,2005,24(8)：26-27.
[32]陈太福.三阴交为主针刺治疗单纯性高脂血症[J].黑龙江中医药,2003,10(1)：43-44.
[33]张唐法,万文俊,张红星等.电针丰隆穴治疗高脂血症的多中心观察[J].中国临床康复,2006,10(19)：17-19.
[34]周喜燕,李滨.针灸治疗痰浊血瘀型高脂血症50例[J].吉林中医药,2005,25(6)：39.
[35]俞文全,许祥贵,吴焕淦.针灸治疗高脂血症的临床研究[J].上海针灸杂志.2011,30(3)：155-157.
[36]老锦雄,潘清洁.温针灸对冠心病血瘀证患者血脂及血液流变学的干预研究[J].上海针灸杂志,2011,30(10)：656-658.
[37]王国明,沈玲哲,温峰云等.瘢痕灸治疗高脂血症40例临床观察[J].中国中医药信息杂志,2000,11(7)：72-73.
[38]黄华超.艾柱灸治疗高脂血症65例[J].实用中医药杂志,2010,26(7)：494-495.
[1]尹倪,陈胜喜,罗万俊等.冠状动脉前降支结扎法制作大鼠急性心肌梗死模型[J].中国医师杂志,2006,8(9)：1193-1195.
[2]孙波,高海成,黄秀英等.冠脉结扎法与给药法制做大鼠心肌缺血模型的比较[J].实验动物学,2010,27(5)：16-18.
[3]陈大宇.内生肌酐清除率测定在肾脏疾病中的应用[J].华夏医学,2010,4(14)：454-455.
[4]IkataJ, Wakatsuki T, Oishi Y, et al. Leukocyte counts and concentration of soluble ashesion molecules as predictors of coronary atherogenesis [J]. Coron Artery Dis.2000,11(6): 445.
[5]Pilar A, Manel S. Tubular and Interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy Am J Nephrol,2003,23:121-128.
[6]Jenny NS, Tracy RP, OggMS, et al. In the eldely, interleukin-6 plasma levels and the polymorphism are associated with the development of cardiovascular disease [J]. Arterioscler Thromb vase Boil,2002,22 (12):2066-2071.